BR112012015500A2 - composição de combinação útil para o tratamento de doenças cardiovasculares - Google Patents

composição de combinação útil para o tratamento de doenças cardiovasculares

Info

Publication number
BR112012015500A2
BR112012015500A2 BR112012015500A BR112012015500A BR112012015500A2 BR 112012015500 A2 BR112012015500 A2 BR 112012015500A2 BR 112012015500 A BR112012015500 A BR 112012015500A BR 112012015500 A BR112012015500 A BR 112012015500A BR 112012015500 A2 BR112012015500 A2 BR 112012015500A2
Authority
BR
Brazil
Prior art keywords
cardiovascular disease
combination composition
composition useful
treating cardiovascular
agpi
Prior art date
Application number
BR112012015500A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Defiante Farmaceutica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defiante Farmaceutica Sa filed Critical Defiante Farmaceutica Sa
Publication of BR112012015500A2 publication Critical patent/BR112012015500A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"composição de combinação últil para o tratamento de doenças cardiovasculares" é descrito o uso de uma combinação que consiste em uma suspensão de microcápsulas que compreende uma ou mais estatinas em ésteres de alquila de agpi n-3 na qual as estatinas estão isoladas do contato com o éster de alquila de agpi n-3 por meio de uma membrana polimérica que pode ser facilmente desintegrada no meio gastrointestinal, para o tratamento de doenças cardiovasculares.
BR112012015500A 2009-12-23 2010-11-30 composição de combinação útil para o tratamento de doenças cardiovasculares BR112012015500A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09180660 2009-12-23
PCT/PT2010/000053 WO2011078712A1 (pt) 2009-12-23 2010-11-30 Composição de combinação útil para tratamento de doenças cardiovasculares

Publications (1)

Publication Number Publication Date
BR112012015500A2 true BR112012015500A2 (pt) 2016-05-03

Family

ID=43855984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015500A BR112012015500A2 (pt) 2009-12-23 2010-11-30 composição de combinação útil para o tratamento de doenças cardiovasculares

Country Status (12)

Country Link
US (1) US20130236551A1 (pt)
EP (1) EP2517697B1 (pt)
JP (1) JP2013515719A (pt)
KR (1) KR20120104270A (pt)
CN (1) CN102665698A (pt)
AU (1) AU2010335077A1 (pt)
BR (1) BR112012015500A2 (pt)
CA (1) CA2785296A1 (pt)
EA (1) EA201200935A1 (pt)
MX (1) MX2012006993A (pt)
SG (2) SG10201408508YA (pt)
WO (1) WO2011078712A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095182A1 (es) 2012-05-07 2015-09-30 Omthera Pharmaceuticals Inc Composiciones de estatinas y ácidos grasos omega-3
EP2692354A1 (en) * 2012-08-03 2014-02-05 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Means for treating heart disease
PT2952209T (pt) 2014-06-04 2018-05-09 Alfasigma Spa Formulações homogéneas compreendendo ácidos gordos poliinsaturados ómega-3 (n-3 pufa) e resveratrol para administração oral
PL2952180T3 (pl) 2014-06-04 2017-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. STAŁE FORMULACJE ZAWIERAJĄCE RESWERATROL I WIELONIENASYCONE KWASY TŁUSZCZOWE OMEGA-3 (n-3 PUFA)
WO2015185240A1 (en) * 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
KR101950907B1 (ko) 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (pt) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
CA2427618A1 (en) 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
ITMI20072142A1 (it) 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3

Also Published As

Publication number Publication date
JP2013515719A (ja) 2013-05-09
MX2012006993A (es) 2012-07-30
US20130236551A1 (en) 2013-09-12
KR20120104270A (ko) 2012-09-20
EA201200935A1 (ru) 2012-12-28
CA2785296A1 (en) 2011-06-30
WO2011078712A1 (pt) 2011-06-30
EP2517697A1 (en) 2012-10-31
SG181446A1 (en) 2012-07-30
CN102665698A (zh) 2012-09-12
AU2010335077A1 (en) 2012-06-14
SG10201408508YA (en) 2015-02-27
EP2517697B1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
BR112012015500A2 (pt) composição de combinação útil para o tratamento de doenças cardiovasculares
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
BRPI0920813A2 (pt) Recipiente de armazenamento de residuos
ATE538665T1 (de) Lipidzusammensetzung zur verbesserung der hirnfunktion
EP3252057A3 (en) Multicyclic compounds and methods of use thereof
BR112012017056A2 (pt) "composições detergentes contendo lipase de bacillus subtilis e métodos para uso das mesmas"
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
BR112014030202A2 (pt) microorganismos e métodos para a produção de 4-hidroxibutirato 1,4-butanodiol e compostos relacionados
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI1105245A2 (pt) composições para conferir hidrofobicidade e impermeabilidade ao cabelo
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
CO6280502A2 (es) Una composicion farmaceutica
WO2009120919A3 (en) Fenofibrate dosage forms
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201491507A1 (ru) Соли кальция и магния в качестве улучшителей скрипучести в очищающих композициях
ES2721750T3 (es) Artículo termoformado con alta rigidez y buena óptica
BRPI0917942A2 (pt) Óleo contendo um ou mais fosfolipídeos de ácidos graxos poli-insaturados de cadeia longa derivados de biomassa.
CL2013001314A1 (es) Composicion de yogur de consistencia espesa que comprende microorganismos probióticos no replicantes.
WO2007092487A3 (en) Materials and methods for identifying agents that modulate norrin. norrin mimetics, and agents identified thereby
SV2011003827A (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
BR112014002057A2 (pt) guia de instrumento
BR112014017220A8 (pt) composições aglutinantes e métodos para fabricar e utilizar as mesmas
BR112014032986A2 (pt) sistemas para o monitoramento do crescimento de nanoestrutura de carbono
FR2927900B1 (fr) Procede de preparation d'alpha-aminoacetals optiquement actifs.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: DEFIANTE FARMACEUTICA, SA. (PT)